Valuation: Axonics, Inc.

Market Cap 3.63B 3.17B 2.91B 2.72B 5.15B 345B 5.23B 34.99B 13.6B 170B 13.62B 13.32B 585B P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 3.31B 2.89B 2.66B 2.48B 4.7B 315B 4.77B 31.93B 12.41B 155B 12.43B 12.16B 534B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
3 years 48.02
Extreme 48.02
71.05
5 years 38.41
Extreme 38.41
79.92
10 years 11.95
Extreme 11.95
79.92
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 30/09/2013
Director of Finance/CFO 41 01/10/2023
Chief Operating Officer 47 31/07/2018
Director TitleAgeSince
Director/Board Member 69 31/01/2018
Chairman 55 28/04/2020
Director/Board Member 74 07/04/2019
Date Insider Type Main position Quantity % Market Cap.
14/11/24Issuer sale

Chief Technology Officer

63,237 0.1237%
14/11/24Issuer sale

Responsable ventes & marketing

109,664 0.2145%
14/11/24Issuer sale

Chief Operating Officer

124,862 0.2443%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-.--%-.--%+42.30% 3.63B
+4.20%-1.85%-17.39%+9.81% 125B
+0.89%-0.57%+2.52%-2.45% 12.77B
+7.83%+2.71%+43.32%+112.92% 8.71B
+2.29%+7.17%-46.92%-71.82% 4.07B
+4.16%+8.39%+25.37%+46.03% 2.73B
+2.53%+23.07%-7.66%-13.28% 1.89B
+3.55%+8.85%-0.99%-23.70% 1.67B
-5.25%-5.89%+179.33%+133.43% 1.46B
Average +2.33%+1.10%+19.73%+25.92% 18.01B
Weighted average by Cap. +3.90%+2.83%-10.13%+14.17%

Financials

2022 2023
Net sales 274M 239M 220M 205M 389M 26.06B 395M 2.64B 1.03B 12.81B 1.03B 1.01B 44.14B 366M 320M 294M 274M 520M 34.88B 528M 3.53B 1.37B 17.15B 1.38B 1.35B 59.09B
Net income -59.7M -52.19M -47.96M -44.7M -84.79M -5.68B -86.08M -576M -224M -2.79B -224M -219M -9.63B -6.09M -5.32M -4.89M -4.56M -8.65M -580M -8.78M -58.72M -22.83M -285M -22.85M -22.36M -982M
Net Debt -348M -304M -280M -261M -494M -33.14B -502M -3.36B -1.31B -16.29B -1.31B -1.28B -56.14B -317M -277M -255M -238M -451M -30.22B -458M -3.06B -1.19B -14.85B -1.19B -1.17B -51.18B
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
797
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. AXNX Stock